The more Perrigo Company PLC has added to its consumer health portfolio, namely the first OTC daily oral contraceptive available in the US, the more it has been hit with lower revenues for some product lines and from some customers.
Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill
OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.
